Pfizer releases promising data on its COVID-19 pill; Republican state officials push back on President Joe Biden's vaccine mandate; some spray deodorants may contain high levels of cancer-causing chemicals.
Data released by Pfizer show that the company’s experimental COVID-19 antiviral pill reduced the risk of death and hospitalization by 89% among patients with newly diagnosed disease, STAT News reports. The pill could signify a turning point in the pandemic, as currently available treatments need to be administered intravenously or as shots. Although data have not been peer reviewed or submitted to regulators, some experts called the news very promising. The announcement comes a day after Merck’s COVID-19 pill was approved in the United Kingdom.
In the wake of President Joe Biden’s release of a more detailed plan for large private employers to vaccinate their workers, several Republican state officials have expressed their objection to the measure and are working to rebuke it, according to the Associated Press. The officials see the plan, which mandates COVID-19 vaccines or weekly testing among employees, as government overreach, and at least 2 conservative groups have already filed lawsuits against implementation. Some states also already passed laws or executive orders to protect employers unwilling to comply.
An independent testing lab in Connecticut filed a petition with the FDA claiming antiperspirant and deodorant body sprays should be recalled because they contain elevated levels of the carcinogen benzene, Bloomberg reports. The cancer-causing chemical has previously been found in aerosol sunscreens and antifungals, while earlier this year Johnson & Johnson recalled certain sunscreen sprays under its Neutrogena and Aveeno brands. Valisure, the testing lab, tested 108 batches of antiperspirant and deodorant sprays and found benzene in 59 batches at levels up to triple the amount found in sunscreens.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More